With trailblazer 23andme Inc. re-emerging in the personal genomics space with a $115 million series E to reinvigorate its direct-to-consumer efforts and the price point for whole genome analysis falling below the important $1,000-per-person barrier, precision medicine (PM) has made its way into the everyday vernacular.